Skip to content
value.today

Traws Pharma, Inc.

TRAW
$5 Mmarket cap on Oct 30, 2026
Compare
World rank
#27,017
Revenue
$3 M
For year ending December-2025
Net income
$9 M
328.7% margin
SEC filing
Employees
7
As of December 31, 2025
SEC filing

Traws Pharma, Inc. in brief

Traws Pharma, Inc. is a listed company in the Biotechnology industry, based in Newtown, Pennsylvania, USA. Its market value was $5 M on 30 October 2026, which makes it the 27,017th largest listed company in the world and the 4,417th largest in the USA on this site. In the year to December 2025 it had sales of $3 M and a net profit of $9 M. It employs about 7 people. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol TRAW (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Traws Pharma, Inc.

Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.

On April 1, 2024, the Company (then known as Onconova Therapeutics, Inc.) consummated a merger with Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID-19 and other infectious diseases. Prior to the Merger, the focus of our business was the discovery and development of novel products for patients with cancer. After completion of the Merger, the focus of our business expanded to include the development of novel therapies to target critical threats to human health in respiratory viral diseases. Following the Merger, we have four clinical programs: (i) tivoxavir marboxil, an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza; (ii) ratutrelvir, an inhibitor of the main protease (also known as 3CL protease) of the SAR-CoV-2 virus, the causative agent in COVID-19; (iii) narazaciclib (ON 123300), a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and (iv) rigosertib, administered alone or in combination for investigation in various cancers. Each of these programs is discussed in additional detail, below.

From the company's annual report filed with the US SEC: read the report

Traws Pharma, Inc. timeline

4 events, 2003–2025
  1. 2003
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2013
  4. 🔔
    Initial public offering as Onconova Therapeutics Inc
    Final prospectus filed with the SEC on 25 July 2013; shares registered for exchange trading on 23 July 2013.
  5. 2024
  6. ✎
    Renamed Traws Pharma, Inc.
    Formerly Onconova Therapeutics Inc.
  7. 2025
  8. 💰
    Record revenue of $3 million
    FY2025, the highest of the 8 years on record.

Events of Traws Pharma, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$2 M$3 M$5 M$7 M

World rank over time

▼ down 430 places since 2026
2026-10-14: #26593#26,59320262026-10-30: #27023#27,0232026

Rank in USA: #4,321 (Oct 2026) · #4,418 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
0.5×
Price / sales
1.7×
Price / book
—
Free cash flow yield
-450.3%
Net margin
328.7%
Operating margin
-640.9%
Return on equity
—
Liabilities / assets
105.9%
Revenue growth
+1113.0%
R&D / revenue
435.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-21M$1MFY18Fiscal year ending Dec 2019: revenue $2M, net income $-22M$2MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-25M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-16M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-19M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-19M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-167M$0MFY24Fiscal year ending Dec 2025: revenue $3M, net income $9M$3MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$3M+1113.0%$-18M$9M328.7%
Dec 2024$0M0.0%$-142M$-167M-72400.0%
Dec 2023$0M0.0%$-20M$-19M-8239.1%
Dec 2022$0M0.0%$-20M$-19M-8243.5%
Dec 2021$0M0.0%$-17M$-16M-7026.1%
Dec 2020$0M-89.4%$-25M$-25M-10939.1%
Dec 2019$2M+77.2%$-22M$-22M-986.2%
Dec 2018$1M—$-23M$-21M-1672.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-18M$3M$-21M$0.82—
Dec 2024$-30M$4M$-33M$-35.21—
Dec 2023$-18M$0M$-18M$-22.57—
Dec 2022$-16M——$-0.91—
Dec 2021$-19M——$-0.96—
Dec 2020$-23M$0M$-23M$-2.17—
Dec 2019$-21M$0M$-21M$-1.49—
Dec 2018$-23M——$-4.99—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue $0M, net income $-8M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $0M, net income $-30M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $21M$0MMar ’25Three months to Jun 2025: revenue $3M, net income $-1M$3MJun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-7M—Dec ’25Three months to Mar 2026: revenue —, net income $-7M—Mar ’26Three months to Jun 2026: revenue —, net income $-3M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Traws Pharma, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$3 M
Operating income
$-18 M
Net income
$9 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$11 M
Total equity
$-1 M

As of December-2025

Top 33 institutional investors in Traws Pharma, Inc.#

As of Sep 30, 2026
33 institutions held 5.9 M shares (about 38.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 34.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Traws Pharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Orbimed Advisors LLC1,203,2600 (0.00%)7.83%$1 MNov 16, 2026
2Ally Bridge Group (NY) LLC786,2360 (0.00%)5.12%$0 MNov 16, 2026
3Adage Capital Partners GP, L.L.C.730,0000 (0.00%)4.75%$0 MNov 16, 2026
4ADAR1 Capital Management, LLC597,7290 (0.00%)3.89%$0 MNov 16, 2026
5Lynx1 Capital Management LP559,4700 (0.00%)3.64%$0 MNov 16, 2026
6Ikarian Capital, LLC478,1420 (0.00%)3.11%$0 MNov 16, 2026
7Sphera Funds Management LTD.398,4860 (0.00%)2.59%$0 MNov 16, 2026
8Citadel Advisors LLC205,680New1.34%$0 MNov 16, 2026
9Alyeska Investment Group, L.P.164,3760 (0.00%)1.07%$0 MNov 16, 2026
10Vanguard Capital Management LLC152,849-177,200 (-53.69%)0.99%$0 MNov 13, 2026
11Boothbay Fund Management, LLC133,9360 (0.00%)0.87%$0 MNov 16, 2026
12Geode Capital Management, LLC110,970-395 (-0.35%)0.72%$0 MNov 6, 2026
13Kynam Capital Management, LP84,4000 (0.00%)0.55%$0 MNov 16, 2026
14Vanguard Fiduciary Trust Co54,5110 (0.00%)0.35%$0 MNov 13, 2026
15HRT Financial LP50,102-41,118 (-45.08%)0.33%$0 MNov 13, 2026
16Northern Trust Corp37,4540 (0.00%)0.24%$0 MNov 16, 2026
17Virtu Financial LLC28,732+16,153 (+128.41%)0.19%$0 MNov 17, 2026
18State Street Corp25,8020 (0.00%)0.17%$0 MNov 12, 2026
19UBS Group AG19,616+16,165 (+468.41%)0.13%$0 MNov 10, 2026
20Jane Street Group, LLC19,085-196,921 (-91.16%)0.12%$0 MNov 12, 2026
21Susquehanna International Group, LLP15,837New0.10%$0 MNov 16, 2026
22Citigroup Inc11,761New0.08%$0 MNov 4, 2026
23StoneX Group Inc.11,106New0.07%$0 MNov 3, 2026
24BlackRock, Inc.8,020-1,921 (-19.32%)0.05%$0 MNov 13, 2026
25Tower Research Capital LLC (TRC)4,861-281 (-5.46%)0.03%$0 MNov 16, 2026
Show all 33: investors 26 to 33
Institutional investors 26 to 33 in Traws Pharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Huntington National Bank4,675-1 (-0.02%)0.03%$0 MNov 10, 2026
27SBI Securities Co., Ltd.1,723+2 (+0.12%)0.01%$0 MOct 22, 2026
28Morgan Stanley837+369 (+78.85%)0.01%$0 MNov 13, 2026
29Federation des caisses Desjardins du Quebec5000 (0.00%)0.00%$0 MNov 16, 2026
30Vanguard Global Advisers, LLC2620 (0.00%)0.00%$0 MNov 13, 2026
31Northwestern Mutual Wealth Management Co5New0.00%$0 MNov 13, 2026
32FMR LLC20 (0.00%)0.00%$0 MNov 10, 2026
33Jones Financial Companies Lllp20 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding Traws Pharma, Inc.#

8 funds hold shares worth $0 M (about 2.5% of the company). Since their previous reports 3 added shares and 1 sold, buying $0 M net.
Mutual funds holding Traws Pharma, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.177,200$0 M1.2%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.152,849$0 M0.99%<0.01%+177%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC39,339$0 M0.26%<0.01%−4.2%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC8,098$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,466$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC743$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.321,970$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.365,661$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC104,398$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC33,198$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC21,108$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC23,169$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.14,441$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC11$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Traws Pharma, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$998 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$998 K
open market only
Insiders on file
33
since
Traws Pharma, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed OrbiMed Capital GP VIII LLC10% ownerBuyindirect+597,729$1.670$998 K1.20 MForm 4
filed Charles Nolan ParkerChief Financial OfficerGrant or award+15,393——15,393Form 4
filed Mary Teresa ShoemakerDirectorGrant or award+6,157——6,292Form 4
filed Trafford ClarkeDirectorGrant or award+6,157——6,157Form 4
filed Robert RedfieldChief Medical OfficerGrant or award+16,419——113,919Form 4
filed John Harold LeamanDirectorGrant or award+4,058——4,058Form 4
filed Charles David PauzaChief Science Officer VirologyGrant or award+18,471——115,971Form 4
filed Nikolay SavchukChief Operating Officer, DirectorGrant or award+16,419——150,606Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Traws Pharma, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
683,674
7.5% of shares · 4.14 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split ; 1-for-14.93 reverse split ; 1-for-14.99 reverse split ; 1-for-10 reverse split ; 1-for-1.33 reverse split

Trading halts

  • 2025-05-13 15:33 UTC, code LUDP, resumed 15:43 UTC
  • 2024-12-27 15:03 UTC, code LUDP, resumed 15:08 UTC
  • 2024-12-23 15:22 UTC, code LUDP, resumed 15:27 UTC
  • 2024-12-23 15:12 UTC, code LUDP, resumed 15:17 UTC
  • 2024-12-23 14:55 UTC, code LUDP, resumed 15:00 UTC

Fails to deliver

  • : 3,911 shares at $0.30
  • : 4,097 shares at $0.36
  • : 56,722 shares at $0.37
  • : 9,892 shares at $0.34
  • : 15,169 shares at $0.34

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Traws Pharma, Inc. scorecard#

Passes 9 of the 17 checks that could be worked out: strongest in growth (4 of 5), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation3 of 4
    • ✓P/E below its peers' median0.5×P/E 0.5× against Biotechnology's median of 17.5×.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✓Earnings yield above the 10-year Treasury yield200.0%Earnings yield 200.0% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • ✓Revenue up more than 5% a year over three years129.8%129.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median129.8%129.8% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year0.82 vs -35.21Diluted EPS 0.82 in fiscal 2025 against -35.21 the year before (report's currency).
    • ✓Net income higher than five years earlier$9 M$9 M in fiscal 2025 against -$25 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability2 of 4
    • ✓Profitable in the newest year$9 MNet income $9 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-640.9%-640.9% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-640.9%-640.9% in fiscal 2025 against -8534.8% in 2022.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.7×Current ratio 0.72 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-89.77Z-score -89.77 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year439.3%Diluted shares up 439.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Traws Pharma, Inc.'s statements, beside the median of Biotechnology.

Traws Pharma, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-640.9%-60.5%
Net margin328.7%-68.9%
Revenue growth, 3 years a year129.8%12.9%
Free cash flow margin-744.1%-61.5%

3of 7on the Piotroski tests of financial strength

  • Free cash flow was negative: -$21 million.
  • Only -198% of net income arrived as cash from operations.
  • The share count rose 439.3% in the year.
  • Shareholders' equity is negative: -$1 million.

Traws Pharma, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Traws Pharma, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue2.80.20.20.20.20.22.21.20.85.5
Research and development121311117.31716171920
General and administrative8.5129.18.49.48.38.37.67.49.2
Operating expenses211432120172524252729
Operating income−18−142−20−20−16−25−22−23−26−24
Interest and finance income0.50.51.40.7——————
Other non-operating income (expense)0.50.31.40.70.00.00.11.20.00.1
Income before tax9.2−167−19−19−16−25−21−21−24−20
Income tax—————0.00.0−0.10.00.0
Net income including minority interests9.2−167−19−19−16−25−22−20−24−20
Minority interests' share of net income———————0.2r——
Net income attributable to shareholders9.2−167−19−19−16−25−22−21−24−20
Earnings per share, basic0.83-35.21-22.57r-0.91-0.96-2.17r-1.49-4.99-40.15r-4.44
Earnings per share, diluted0.82-35.21-22.57r-0.91-0.96-2.17r-1.49-4.99-40.15r-4.44
Shares, weighted average (basic)8.21.60.8r211712————
Shares, weighted average (diluted)8.41.60.8r211712r144.10.6r4.4
Balance sheet
Cash and cash equivalents3.8212139551923174.021
Receivables3.81.80.00.00.00.00.10.00.10.0
Other current assets0.10.20.40.00.00.20.10.10.10.1
Current assets8.0252339552023184.923
Property, plant and equipment0.00.00.00.00.00.10.10.00.10.2
Other intangible assets2.5—————————
Total assets11252339552024185.023
Accounts payable5.78.25.63.92.84.84.34.06.25.3
Current liabilities11129.28.06.1108.38.410.010
Total liabilities115712119.41412131618
Retained earnings−640−649−483−464−445−429−403−382−362−338
Shareholders' equity——————125.4−124.3
Minority interests————————0.80.8
Total equity−0.6−321128466.2125.4−115.1
Total liabilities and equity11252339552024185.023
Shares outstanding9.13.70.8r212112r1115.70.7r6.8
Cash-flow statement
Depreciation and amortization0.10.00.00.00.00.00.00.10.10.1
Share-based compensation0.71.41.31.20.60.41.01.11.73.9
Cash from operating activities−18−30−18−16−19−23−21−23−24−16
Capital expenditure−2.6−3.6−0.0——−0.0−0.1———
Cash from investing activities−2.6−3.6−0.0——−0.0−0.1———
Shares issued5.6———559.12235——
Cash from financing activities3.234——561927366.417
Exchange-rate effect on cash0.0−0.00.0−0.0−0.00.0−0.0−0.00.0−0.0
Change in cash−180.5−18−1636−3.75.813−171.6
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Traws Pharma, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Single reportable segment$3 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Traws Pharma, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 3 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 5

Traws Pharma, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Acquisition or sale completedMaterial agreement8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 23, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Traws Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2018$1 MPrivate placement after listingUnder $2 million1equitySEC
Oct 2015$2 MPrivate placement after listingUnder $2 million1equitySEC
Jul 2012$50 MNo. 4$50 to $250 million1equitySEC
Apr 2012$26 MNo. 3$10 to $50 million41equity, optionsSEC
Sep 2010$12 MNo. 2$10 to $50 million67equitySEC
May 2009$19 MNo. 1$10 to $50 million58equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Traws Pharma, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
12
2016–2016
Latest
6 people
2016-08-30
Traws Pharma, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2016·6·····6····12
Traws Pharma, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
6 people (21% of workforce)Restructuring planSEC 8-K“The Company estimates the net reduction to be approximately 6 employees, which represents approximately 21 percent of its workforce.”Filing
6 people (17% of workforce)Restructuring planSEC 8-K“The Company estimates the net reduction to be approximately 6 employees, which represents approximately 17 percent of its workforce.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Traws Pharma, Inc. compares in Biotechnology

  • Market cap$5 M · higher than 5% of 726
  • Revenue$3 M · higher than 32% of 647
  • Revenue growth1113.0% · higher than 98% of 438
  • P/E ratio0.5× · lowest of 100
  • Price / sales1.6× · lower than 88% of 339

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Traws Pharma, Inc.🇺🇸$5 M0.5×—+1113.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Traws Pharma, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Traws Pharma, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Traws Pharma, Inc.? Suggest a correction